Approfondimenti generali
Tumore del rene, Linee Guida AIOM, 2021. [Apri]
Renal Cell Carcinoma: ESMO Clinical Practice Guidelines. [Apri]
NCCN Guidelines - Kidney cancer. [Apri] A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Choueiri TK, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2021; 384: 829–841. [Apri]
Apolo AB, et al. Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial. ASCO 2021. Abstract 4553. [Apri]
Powles T, et al. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.ASCO GU 2022. Abstract 350. [Apri]